---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Budget impact"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Budget impact. Topics: Summary: eligible population inputs and Summary: comparator regimen costs and cost of recurrent or metastatic disease. 3 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary/budget-impact"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Budget impact

<a id="heading-1.1.3"></a>

## 1.1.3 Budget Impact of Ficerafusp alfa

<a id="topic-1.1.3-1"></a>

### Summary

Ficerafusp alfa is investigational. No price, wholesale acquisition cost, budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa was found. Bicara states that ficerafusp alfa “may be priced at a significant premium over competitive products if any have been approved by then” and expects an interim analysis of FORTIFI-HN01 in mid-2027 “to support a potential approval and U.S. launch in 2028.” In FORTIFI-HN01, every participant receives pembrolizumab 200 mg every 3 weeks for up to 35 cycles, with ficerafusp alfa or placebo given weekly until disease progression or unacceptable toxicity; the cost of ficerafusp alfa would therefore be added to the cost of pembrolizumab for each treated patient.

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4); [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm); [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-1.1.3-2"></a>

### Summary: eligible population inputs

The American Cancer Society estimates 60,480 new cases of oral cavity and pharynx cancer and 12,290 new cases of laryngeal cancer in the United States in 2026; these counts include all histologies and both HPV-negative and HPV-positive disease. Bicara's Form 10-K states that over 90% of head and neck cancer cases are of squamous cell origin, that an estimated 10% of patients have metastatic disease at diagnosis and “up to 30% of additional patients develop a recurrence or metastases over time after initial treatment for advanced HNSCC”, and that an estimated 80% of recurrent or metastatic HNSCC is HPV-negative. In a U.S. real-world cohort treated in the first-line recurrent or metastatic setting, 60.4% of participants had non-HPV associated disease, and 1410 participants (54.7%) received anti-PD-1 monotherapy, 577 (22.4%) anti-PD-1 plus chemotherapy, and 590 (22.9%) cetuximab plus chemotherapy. The pivotal trial requires PD-L1 CPS ≥1; in the first-line trial described in the pembrolizumab label, 85% of tumors had CPS ≥1. Bicara's presentation estimates “~18K” HPV-negative patients newly diagnosed each year in the United States (“~50K” in the United States, EU5, and Japan), based on “Tessellon patient flow modeling; SEER; country-specific registries; literature review”.

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf); [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm); [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12099209/); [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990); [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="topic-1.1.3-3"></a>

### Summary: comparator regimen costs and cost of recurrent or metastatic disease

Merck lists the price of pembrolizumab at $12,517.44 for each dose given every 3 weeks and $25,034.88 for each dose given every 6 weeks, current as of September 2026. The pembrolizumab label gives treatment for HNSCC as “Until disease progression, unacceptable toxicity, or up to 24 months”, and median real-world time on first-line pembrolizumab monotherapy was 4.2 months (95% CI, 3.5–4.6). Lilly lists cetuximab at $17,235.60 per month for an average-sized patient. In a retrospective study using the Vector Oncology Data Warehouse, the mean monthly health care cost was $14,391 (95% CI, 12,739-16,044), with hospitalization representing about 57% of the total. Among 716 participants treated before or after the introduction of immuno-oncology agents, per patient per month total costs of care in first-line post-platinum therapy were $11,535 after and $9,054 before (p=.002). In 2004 to 2008 Medicare and commercial claims, 6-month incremental adjusted total costs were $60,414 per patient for metastatic and $21,141 per patient for recurrent head and neck cancer. In SEER-Medicare, recurrence of locally advanced HNSCC was associated with higher monthly health care costs of $3,831 (resected) and $4,730 (unresected). None of these cost studies is restricted to HPV-negative disease.

Source: [Merck KEYTRUDA cost information (2026)](https://www.keytruda.com/financial-support/); [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/); [Lilly ERBITUX cost information (2026)](https://www.lillypricinginfo.com/erbitux); [Fisher et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29530457/); [Abraham et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31581922/); [Kim et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22475042/); [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
